| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Specific molecular target information for Glyasperin F is not fully detailed. As a flavonoid, its mechanism involves interaction with cellular structures and proteins, including potential inhibition of nitric oxide synthase (iNOS), modulation of NF-kappaB signaling, and scavenging of free radicals [20L26-L29]. Flavonoids are known to target various enzymes and receptors, including cyclooxygenases (COX), lipoxygenases (LOX), and kinases. Glyasperin F displays antinociceptive (pain-relieving) and anti-inflammatory effects, and can inhibit NO production in RAW 264.7 macrophages, indicating activity in the inflammatory pathway [20L26-L29].
|
|---|---|
| ln Vitro |
Glyasperin F displays cytotoxic effects against four tested cancer cell lines with IC50 values below 85 uM, indicating moderate anticancer activity [20L28-L29]. It also exhibits antinociceptive (pain-relieving) and anti-inflammatory effects, and can inhibit nitric oxide (NO) production in RAW 264.7 macrophages to some extent [20L26-L29]. The specific IC50 values for each cancer cell line and the exact concentration for NO inhibition are not provided. The cytotoxicity and anti-inflammatory activities suggest potential therapeutic applications.
|
| ln Vivo |
Specific in vivo activity data for Glyasperin F is not provided in the search results. However, the compound has been shown to display antinociceptive (pain-relieving) effects and anti-inflammatory effects, suggesting that it has activity in animal models of pain and inflammation [20L26-L28]. Further in vivo studies would be required to assess its efficacy and pharmacokinetic profile.
|
| Enzyme Assay |
Not applicable. Glyasperin F is a natural product and is not typically used in cell-free enzyme inhibition assays. Its anti-inflammatory activity can be assessed by measuring inhibition of purified iNOS or COX-2 enzymes, but specific protocols are not provided. Its characterization involves standard analytical methods such as HPLC, NMR, and MS to confirm identity and purity. The compound is stored as a powder at -20degC [20L4-L6].
|
| Cell Assay |
The anti-inflammatory and cytotoxic activity of Glyasperin F can be assessed in RAW 264.7 macrophages and cancer cell lines. Procedure: For anti-inflammatory studies, RAW 264.7 macrophages are seeded in 96-well plates (1×10⁵ cells/well). Cells are pre-treated with varying concentrations of Glyasperin F (1-100 uM) for 1 hour, then stimulated with lipopolysaccharide (LPS, 1 ug/mL) for 24 hours. NO production in the culture supernatant is measured using the Griess reagent. Cell viability is assessed by MTT assay to ensure non-cytotoxicity at tested concentrations. The IC50 for NO inhibition is calculated. For cytotoxicity studies, four cancer cell lines (likely including HeLa, MCF-7, A549, HCT116) are seeded in 96-well plates (5×103 cells/well) and treated with Glyasperin F (1-100 uM) for 48-72 hours. Cell viability is measured by MTT or CellTiter-Glo assay. Reported IC50 values are below 85 uM [20L28-L29].
|
| Animal Protocol |
The antinociceptive and anti-inflammatory effects of Glyasperin F can be evaluated in a mouse model of acute inflammation. Procedure: Male ICR mice (20-25 g, n=10 per group) are fasted overnight. Glyasperin F is dissolved in a suitable vehicle (e.g., DMSO:Tween 80:Saline = 10:5:85) and administered orally or intraperitoneally at doses of 10, 20, and 40 mg/kg. For the carrageenan-induced paw edema model (acute inflammation), 1 hour after compound administration, 50 uL of 1% λ-carrageenan is injected into the right hind paw. Paw volume is measured using a plethysmometer at 0, 1, 2, 3, 4, 5, and 6 hours post-carrageenan. Percent inhibition of edema is calculated. For antinociceptive activity, the acetic acid-induced writhing test is performed: 30 minutes after compound administration, 0.6% acetic acid (10 mL/kg) is injected intraperitoneally. The number of abdominal writhes (stretching movements) is counted over 20 minutes. A reduction in writhing number indicates antinociceptive activity.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Glyasperin F is not available. As a flavonoid with a molecular weight of 354.35 g/mol, it is expected to have moderate oral bioavailability, though absorption and metabolism are highly variable depending on glycosylation (Glyasperin F is a non-glycosylated aglycone). Flavonoid aglycones generally have better absorption than glycosylated forms. Without specific data, its half-life and tissue distribution cannot be assessed.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for Glyasperin F is not provided. As a natural flavonoid, it is presumed to have low toxicity at research concentrations. The reported IC50 values for cytotoxicity are below 85 uM, indicating that it can kill cancer cells at relatively low concentrations, suggesting a potential therapeutic window. Standard laboratory safety precautions for handling organic compounds should be followed.
|
| Additional Infomation |
Reports indicate that glycyrrhizin F is found in licorice, coarse licorice, and coral tree, and relevant data are available for reference.
Glyasperin F (also known as (-)-Glyasperin F) is a flavonoid isolated from the roots of Glycyrrhiza aspera Pall. (coarse licorice) and other Glycyrrhiza species [20L4-L6]. Licorice root has been used in traditional medicine for its anti-inflammatory, demulcent, and hepatoprotective properties. Glyasperin F displays antinociceptive (pain-relieving) and anti-inflammatory effects, and can inhibit nitric oxide (NO) production in macrophages to some extent [20L26-L29]. The compound also displays cytotoxic effects against four tested cancer cell lines with IC50 values below 85 uM [20L28-L29]. These properties make it a subject of interest for cancer and inflammation research. The compound is for research use only and is not an approved drug. |
| Molecular Formula |
C20H18O6
|
|---|---|
| Molecular Weight |
354.35
|
| Exact Mass |
354.11
|
| CAS # |
145382-61-2
|
| PubChem CID |
392442
|
| Appearance |
Typically exists as solids at room temperature
|
| Source |
Originated from plants: Leguminosae Glycyrrhiza aspera Pall.
|
| LogP |
3.347
|
| tPSA |
96.22
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
26
|
| Complexity |
587
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C2C(=C(C=CC=2C2C(C3C(=CC(=CC=3OC2)O)O)=O)O)C=CC1(C)C
|
| InChi Key |
CFCUNFSHJIQKLS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H18O6/c1-20(2)6-5-12-14(22)4-3-11(19(12)26-20)13-9-25-16-8-10(21)7-15(23)17(16)18(13)24/h3-8,13,21-23H,9H2,1-2H3
|
| Chemical Name |
5,7-dihydroxy-3-(5-hydroxy-2,2-dimethylchromen-8-yl)-2,3-dihydrochromen-4-one
|
| Synonyms |
Licorice F
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8221 mL | 14.1103 mL | 28.2207 mL | |
| 5 mM | 0.5644 mL | 2.8221 mL | 5.6441 mL | |
| 10 mM | 0.2822 mL | 1.4110 mL | 2.8221 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
